Studying combined targeted therapies for large B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of two immunotherapy drugs (rimegepant and glofitamab) plus a special cell therapy called CD19 CAR-T for people with large B-cell lymphoma that has not responded to or has returned after previous treatment. The goal is to see if this combination can better control the lymphoma and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older and have a confirmed diagnosis of large B-cell lymphoma (a type of blood cancer).
- Your lymphoma must have come back or not responded after at least one previous treatment that included chemotherapy and an antibody therapy like rituximab.
- You need at least one high-risk feature, such as lymphoma outside the lymph nodes, a large tumor mass, or a TP53 gene change.
- You should be generally able to care for yourself (ECOG score 0-2) and have enough healthy organ function (bone marrow, liver, kidneys, lungs, heart).
- You cannot have had a prior stem cell transplant from a donor or an organ transplant.
- You must not have active infections, serious heart disease, or untreated nervous system involvement.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of CAR-T cell therapy and a drug called glofitamab for people with large B-cell lymphoma that has come back or not responded to treatment. The goal is to see if this combo can help those with high-risk features.
This study tests a new combination of medicines, chosen based on your tumor's specific features, for people whose lymphoma did not respond to CD19 CAR-T therapy. The goal is to find a more effective treatment option for this difficult situation.
This study tests a new combination of four drugs—sonrotoclax, glofitamab, gemcitabine, and oxaliplatin—in people with large B-cell lymphoma that has come back or not responded to earlier treatment. The goal is to see if this combination can shrink or control the lymphoma.
This trial tests a new combination of drugs (glofitamab plus GemOx) against the usual treatment for people whose diffuse large B-cell lymphoma (a type of blood cancer) has returned or not gone away after initial therapy. The goal is to see if this new approach works better and helps you live longer.
This trial combines two treatments for large b-cell lymphoma that has come back or not responded to previous therapy. Glofitamab is a drug that helps the immune system attack cancer cells, and CAR-T therapy uses your own white blood cells, which are modified in a lab to find and kill cancer cells. This study aims to see if the two treatments together are safe and effective.
This trial tests two immune-based treatments—first a special type of immunotherapy (CAR T-cells, called axi-cel), then a targeted antibody drug (glofitamab)—for people with large B-cell lymphoma that did not fully respond to their first treatment or came back within a year. The goal is to see if this combination can help more people achieve lasting remission.
Hear when a new Relapsed/Refractory Large B-cell Lymphoma (LBCL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.